Benefits of delapril in hypertensive patients along the cardiovascular continuum

González-Juanatey, José Ramón; Cordero, Alberto

doi:10.1586/erc.12.188

Cited by 4 publications

(2 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…40 The lack of relation between serum 25(OH)D and lipid profile was supported by recent serial clinical laboratory data analysis. 41 We performed interaction tests which suggested there is no multiplicative effect of statin use on the relation between serum 25(OH)D and vascular function. This suggests that statin-induced increases in serum 25(OH)D have similar effects to vitamin D obtained from other natural sources including dietary intake and sunlight exposure.…”

Section: Discussionmentioning

confidence: 99%

Vascular protective effects of statin-related increase in serum 25-hydroxyvitamin D among high-risk cardiac patients

Chan¹,

Lau²,

Yiu³

et al. 2015

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Vascular protective effects of statin-related increase in serum 25-hydroxyvitamin D among high-risk cardiac patients

Chan¹,

Lau²,

Yiu³

et al. 2015

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

show abstract

“…On the other hand, other studies have analyzed the antihypertensive efficacy of a combination of indapamide and delapril in hypertensive patients 79–82. In DIMS II (Delapril-Indapamide Multicenter Study II), approximately 800 patients with uncomplicated mild to moderate hypertension were randomized to receive delapril/indapamide or captopril/HCTZ for 6 months.…”

Section: Efficacy and Safety Of Indapamidementioning

confidence: 99%

Which thiazide to choose as add-on therapy for hypertension?

Barrios¹,

Escobar²

2014

IBPC

View full text Add to dashboard Cite

Combined therapy is required in the majority of patients with hypertension to achieve blood pressure (BP) targets. Although different antihypertensive drugs can be combined, not all combinations are equally effective and safe. In this context, the combination of a renin angiotensin system inhibitor with a diuretic, usually a thiazide, particularly hydrochlorothiazide (HCTZ) or thiazide-like diuretics, such as chlorthalidone or indapamide, is recommended. However, not all diuretics are equal. Although HCTZ, chlorthalidone, and indapamide as add-on therapy effectively reduce BP levels, the majority of studies have obtained greater BP reductions with chlorthalidone or indapamide than with HCTZ. Moreover, there are data showing benefits with chlorthalidone or indapamide beyond BP. Thus, chlorthalidone seems to have pleiotropic effects beyond BP reduction. Moreover, compared with placebo, chlorthalidone has small effects on fasting glucose and total cholesterol, and compared with HCTZ, chlorthalidone achieves significantly lower total cholesterol and low-density lipoprotein cholesterol levels. Similarly, indapamide has demonstrated no negative impact on glucose or lipid metabolism. More importantly, although head-to-head clinical trials comparing the effects of indapamide or chlorthalidone with HCTZ are not available, indirect comparisons and post hoc analyses suggest that the use of chlorthalidone or indapamide is associated with a reduction in cardiovascular events. Despite this, the most frequent diuretic used in clinical practice as add-on therapy for hypertension is HCTZ. The purpose of this review is to update the published data on the efficacy and safety of HCTZ, chlorthalidone, and indapamide as add-on therapy in patients with hypertension.

show abstract